What is Aptimmune?
Aptimmune Biologics is at the forefront of developing advanced mucosal vaccines designed to address significant threats to the swine industry, including Porcine Reproductive and Respiratory Syndrome (PRRS) virus and Swine Influenza A virus. Leveraging its proprietary Barricade platform technology, the company offers innovative solutions to stakeholders across various geographical regions. Aptimmune is also actively engaged in research and development for vaccines targeting the African Swine Fever virus, aiming to enhance disease protection and improve overall animal health within the global swine population.
How much funding has Aptimmune raised?
Aptimmune has raised a total of $10.6M across 3 funding rounds:
Private Equity
$2.4M
Series A
$2.2M
Series B
$6M
Private Equity (2015): $2.4M, investors not publicly disclosed
Series A (2017): $2.2M led by Fox Ventures, LLC and Arsenal Capital Management
Series B (2018): $6M supported by Missouri Technology, St Louis Arch Angels, Arsenal Capital Management, Yield Lab, and Cultivation Capital
Key Investors in Aptimmune
Arsenal Capital Management
Arsenal Capital Partners is a leading private equity firm specialized in investments in middle-market industrial growth and healthcare companies. Since its inception in 2000, the firm has distinguished itself through a "build-for-tomorrow" philosophy, focusing on high-growth, technology-, and innovation-rich businesses that are strategically important to their respective markets.
Cultivation Capital
Cultivation Capital is a venture capital firm that invests in young companies with transformative ideas across various industries, including life sciences, software, agriculture, and geospatial technology. The firm provides capital resources and a vast network of partners to help startups navigate the challenges of hyper growth from Series Seed through Series B.
Yield Lab
The Yield Lab is dedicated to enabling entrepreneurs to sustainably revolutionize agrifood systems globally by investing in and advancing high-impact early-stage agrifoodtech companies. They operate through a network of four regional funds, each with its own focus, team, and investor base, while maintaining close relationships to leverage insights and expertise for the benefit of over 90 portfolio companies and investors.
What's next for Aptimmune?
The recent major strategic investment in Aptimmune Biologics, following substantial prior financing rounds, indicates a strong market confidence in the company's innovative vaccine technologies and its potential to address critical unmet needs in animal health. This capital infusion is expected to accelerate the development and commercialization of its Barricade platform, particularly for vaccines targeting PRRS and African Swine Fever. Aptimmune is likely to focus on expanding its research and development capabilities, scaling manufacturing operations, and broadening its market reach to key agricultural regions. Strategic partnerships and further clinical trials may also be on the horizon as the company solidifies its position as a leader in swine disease prevention.
See full Aptimmune company page
